Price T Rowe Associates Inc Lyell Immunopharma, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,731,477 shares of LYEL stock, worth $10.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,731,477
Previous 6,638,883
1.39%
Holding current value
$10.2 Million
Previous $12.9 Million
16.56%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding LYEL
# of Institutions
128Shares Held
144MCall Options Held
0Put Options Held
5.9K-
Mwg Management Ltd. Washington, DC20.2MShares$30.4 Million33.29% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$22.8 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$22.8 Million19.02% of portfolio
-
Black Rock Inc. New York, NY13.9MShares$21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.4MShares$20.2 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $374M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...